<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Le, Huong</style></author><author><style face="normal" font="default" size="100%">Vishwanathan, Nandita</style></author><author><style face="normal" font="default" size="100%">Jacob, Nitya M.</style></author><author><style face="normal" font="default" size="100%">Gadgil, Mugdha</style></author><author><style face="normal" font="default" size="100%">Hu, Wei-Shou</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cell line development for biomanufacturing processes: recent advances and an outlook</style></title><secondary-title><style face="normal" font="default" size="100%">Biotechnology Letters</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomanufacturing</style></keyword><keyword><style  face="normal" font="default" size="100%">Biosimilars</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell line development</style></keyword><keyword><style  face="normal" font="default" size="100%">CHO cells genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome editing</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptomics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">AUG</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">8</style></number><publisher><style face="normal" font="default" size="100%">SPRINGER</style></publisher><pub-location><style face="normal" font="default" size="100%">VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS</style></pub-location><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">1553-1564</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;At the core of a biomanufacturing process for recombinant proteins is the production cell line. It influences the productivity and product quality. Its characteristics also dictate process development, as the process is optimized to complement the producing cell to achieve the target productivity and quality. Advances in the past decade, from vector design to cell line screening, have greatly expanded our capability to attain producing cell lines with certain desired traits. Increasing availability of genomic and transcriptomic resources for industrially important cell lines coupled with advances in genome editing technology have opened new avenues for cell line development. These developments are poised to help biosimilar manufacturing, which requires targeting pre-defined product quality attributes, e.g., glycoform, to match the innovator's range. This review summarizes recent advances and discusses future possibilities in this area.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">1.639</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gadgil, Mugdha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cell culture processes for biopharmaceutical manufacturing</style></title><secondary-title><style face="normal" font="default" size="100%">Current Science</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biopharmaceutical</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell line development</style></keyword><keyword><style  face="normal" font="default" size="100%">CHO</style></keyword><keyword><style  face="normal" font="default" size="100%">glycosylation</style></keyword><keyword><style  face="normal" font="default" size="100%">monoclonal antibody</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">APR </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">112</style></volume><pages><style face="normal" font="default" size="100%">1478-1488</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Recombinant proteins manufactured using animal cell culture processes comprise a significant fraction of biopharmaceuticals. With the expiry of patents on this class of therapeutics, there is also a significant interest in manufacture of biosimilar versions of such therapeutics. This article provides a birds-eye view of upstream process development for animal cell culture processes, with a focus on advances pertinent to the development of processes for biosimilars.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">Indian</style></custom3><custom4><style face="normal" font="default" size="100%">0.883</style></custom4></record></records></xml>